|Traded as||ASX: AVH
|Headquarters||Perth, Western Australia
Cambridge, United Kingdom
Woburn, Massachusetts, USA
|Key people||William F. Dolphin, CEO|
Avita Medical is a clinical and commercial company developing and marketing spray-on skin to treat skin trauma, including burns and scars. The regenerated skin product is currently marketed as a kit named ReCell. ReCell has been approved for marketing and sale in EMEA countries, Canada and Australia.
ReCell, Spray-on Skin
ReCell is a stand-alone, rapid, autologous cell harvesting, processing and delivery technology that enables clinicians to treat wounds and skin defects using very small samples of the patient’s own cells, accelerating the healing process, eliminating tissue rejection, minimizing scar formation and reintroducing normal pigmentation, vascularization and innervation in the treated wound area. The procedure is performed entirely on site at bedside, utilizes a patented and proprietary ‘spray-on’ application technique, takes approximately 25 min to complete and does not require laboratory facilities, off-site culture of tissues or specialized staff. ReCell is approved in EMEA countries, China, and Australia and is in Pivotal/PIII trials in the US for burns as a first indication and a Pilot/PII US study underway for scars.
US Government grant
In 2009 the United States Armed Forces Institute of Regenerative Medicine provided Avita with a US$1.45 million grant to hasten the approval of the ReCell kit with the U.S. Food and Drug Administration.
In addition to the US studies for ReCell in burns and scars, ReCell is being studied in a number of small scale post-marketing studies in Europe for venous leg ulcers, Vitiligo, acne scars, scar remodeling, facial rejuvenation (wrinkle revision), treatment of donor graft sites, and hard to heal burn wounds in the elderly.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|